Access for the terminally ill to experimental medical innovations: a three-pronged threat.
Bender
Shira
S
University of Pennsylvania, USA.
Flicker
Lauren
L
Rhodes
Rosamond
R
D015982:Bias; D017321:Clinical Trials, Phase I as Topic; D004341:Drug Evaluation / Q000191:economics / Q000941:ethics / Q000331:legislation & jurisprudence; D004345:Drug Industry / Q000191:economics / Q000941:ethics / Q000331:legislation & jurisprudence; D015507:Drugs, Investigational / Q000592:standards / Q000627:therapeutic use; D028663:Ethical Theory; D019317:Evidence-Based Medicine; D005260:Female; D006297:Health Services Accessibility / Q000941:ethics / Q000331:legislation & jurisprudence; D006801:Humans; D016365:Liability, Legal; D008119:Lobbying; D008389:Marketing of Health Services / Q000191:economics / Q000941:ethics / Q000331:legislation & jurisprudence; D008402:Mass Media; D028701:Patient Rights; D012941:Social Responsibility; D019452:Terminally Ill / Q000523:psychology; D035703:Therapies, Investigational / Q000592:standards; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D019564:Unnecessary Procedures
D015507:Drugs, Investigational